BioMarin Pharmaceutical Inc. (BMRN)
| Previous close | 82.44 |
| Open | 83.20 |
| Bid | 82.65 x 100 |
| Ask | 82.99 x 200 |
| Day's range | 82.47 - 83.58 |
| 52-week range | 76.02 - 99.56 |
| Volume | |
| Avg. volume | 1,578,145 |
| Market cap | 15.729B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 78.15 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in children with achondroplasia, as well as positive data for investigational uses in growth-related conditions, including idiopathic short stature (ISS) and Noonan syndrome, were presented at the 2024 Pediatric Endocrine Society (PES) Annual Meeting in Chicago, May 2-5, 2024. Researchers also presented results from additional studies highlighting the medicine'
- PR Newswire
BioMarin Reports Record Financial Results for the First Quarter 2024
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the quarter ended March 31, 2024.
- PR Newswire
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24, at 4:30 p.m. ET to discuss first quarter 2024 financial results and provide a general business update.
